Erythromycin Estolate

Gastroparesis, Erythrasma, Whooping Cough + 60 more

Treatment

68 FDA approvals

20 Active Studies for Erythromycin Estolate

What is Erythromycin Estolate

Erythromycin

The Generic name of this drug

Treatment Summary

Erythromycin is an antibiotic that is used to treat a variety of bacterial infections. It was first discovered in 1952 and belongs to a group of antibiotics known as macrolides, which also includes azithromycin, clarithromycin, and spiramycin. Erythromycin can be administered intravenously, topically, or as eye drops.

Erythrocin Stearate

is the brand name

image of different drug pills on a surface

Erythromycin Estolate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Erythrocin Stearate

Erythromycin

1964

261

Approved as Treatment by the FDA

Erythromycin, also known as Erythrocin Stearate, is approved by the FDA for 68 uses which include Acne Vulgaris and Acne Vulgaris .

Acne Vulgaris

Used to treat Acne Vulgaris in combination with Tretinoin

Acne Vulgaris

Used to treat predominant skin comedones, papules and pustules in combination with Tretinoin

Corynebacterium Infections

Urethritis

Staphylococcus (S.) Aureus Infection

urogenital infections during pregnancy

Pertussis

treponema pallidum infection

Diphtheria

penicillins

Bacterial Infections

Communicable Diseases

Conjunctivitis

Respiratory Tract Infections

Erythrasma

Postoperative Infections

Listeriosis

Corynebacterium minutissimum infection

Recurrent Upper and Lower Respiratory Tract Infections (RTIs)

Pneumonia, Mycoplasma

Whooping Cough

Bordetella Pertussis Infection

uncomplicated endocervical infection

Staphylococcal Skin Infections

Communicable Diseases

pustular lesions

Used to treat pustular lesions in combination with Avobenzone

Communicable Diseases

Bacterial Infections

Whooping Cough

Pneumonia

Listeria infection

Listeria monocytogenes infection

Acute Otitis Media caused by Haemophilus Influenzae

Used to treat Acute Otitis Media caused by Haemophilus Influenzae in combination with Sulfisoxazole

inflammatory papular lesions

Used to treat inflammatory papular lesions in combination with Avobenzone

Amebiasis

Common Cold

Rheumatic Fever

prophylaxis of Postoperative Infections

Communicable Diseases

prophylaxis of Rheumatic fever

Ureaplasma urethritis

penicillins

Upper Respiratory Tract Infection

Streptococcus Pneumoniae Infections

Streptococcus pyogenes

Staphylococcal Skin Infections

Urethritis

Urinary Tract Infection (UTI)

Legionella pneumophila

Primary Syphilis

Lower Respiratory Tract Infection (LRTI)

Intestinal amebiasis caused by entamoeba histolytica

Skin and skin structure infections

Corynebacterium Infections

diphtheria antitoxin

Bronchitis

Haemophilus Influenzae Infections

Used to treat Haemophilus Influenzae Infections in combination with null

Urethritis

Ureaplasma urealyticum

skin and subcutaneous tissue bacterial infections caused by streptococcus pyogenes

Whooping Cough

Chlamydia Trachomatis

patients with intolerance or contraindications to tetracycline use

Syphilis

First episode of rheumatic fever

Rheumatic Fever

Pneumococcal Infections

Sulfonamides

Effectiveness

How Erythromycin Estolate Affects Patients

Erythromycin works by preventing bacteria from making proteins, treating bacterial infections. It is important to check if the bacteria is resistant to erythromycin before using it as a treatment. Side effects of erythromycin may include pseudomembranous colitis, which can range from mild to serious, and liver damage. Certain strains of Haemophilus influenzae are more susceptible to erythromycin when used in combination with sulfonamides.

How Erythromycin Estolate works in the body

Erythromycin works to fight bacteria by blocking their ability to make proteins. It does this by binding to the ribosomes, which are essential for making proteins. This stops the bacteria from making proteins and prevents them from replicating. Erythromycin has a strong affinity for bacterial ribosomes, so it works well against a wide range of bacterial infections.

When to interrupt dosage

The proposed dose of Erythromycin Estolate is contingent upon the established condition, like Chlamydia Trachomatis, penicillins and Syphilis. The quantity of dosage is based on the method of administration (e.g. Granule, for suspension or Tablet, film coated - Oral) specified in the table beneath.

Condition

Dosage

Administration

Granuloma Inguinale

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Urethritis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Respiratory Tract Infections

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Endophthalmitis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Ophthalmia neonatorum (gonococcal)

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Conjunctivitis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Amebiasis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Rheumatic Fever

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Communicable Diseases

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Chlamydia Trachomatis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Streptococcus pyogenes

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

diphtheria antitoxin

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

urogenital infections during pregnancy

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Syphilis

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Acne Vulgaris

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Communicable Diseases

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Rheumatic Fever

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Corynebacterium Infections

, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg

, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Granule, for suspension - Oral, Suspension, Suspension - Oral, Granule, for suspension, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Powder, for solution - Oral, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab - Topical, Lotion; Swab, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Capsule, Delayed Release - Oral, Ointment - Topical, Wafer, Wafer - Oral, Capsule, coated pellets - Oral, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated

Warnings

Erythromycin Estolate has nine contraindications and should not be unified with the ailments specified in the following table.

Erythromycin Estolate Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Erythromycin may interact with Pulse Frequency

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Erythromycin Estolate.

Common Erythromycin Estolate Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Erythromycin.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Erythromycin.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Erythromycin.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Erythromycin.

Aminophylline

Major

The metabolism of Aminophylline can be decreased when combined with Erythromycin.

Erythromycin Estolate Toxicity & Overdose Risk

The lowest toxic dose of erythromycin for rats has been found to be 9272 mg/kg. Overdosing on erythromycin can cause diarrhea, nausea, stomach pain, and vomiting. If an overdose occurs, the drug should be stopped and any unabsorbed drug should be eliminated quickly. Additionally, supportive measures should be taken and dialysis is not effective in removing erythromycin.

Erythromycin Estolate Novel Uses: Which Conditions Have a Clinical Trial Featuring Erythromycin Estolate?

53 active clinical trials are currently investigating the potential of Erythromycin Estolate to combat Streptococcus pyogenes, treponema pallidum infection and Rheumatic Fever.

Condition

Clinical Trials

Trial Phases

Acne Vulgaris

3 Actively Recruiting

Phase 1, Phase 2, Early Phase 1, Phase 4

Listeriosis

0 Actively Recruiting

Legionella pneumophila

0 Actively Recruiting

Urethritis

0 Actively Recruiting

Ureaplasma urealyticum

0 Actively Recruiting

Acute Otitis Media caused by Haemophilus Influenzae

0 Actively Recruiting

Gastroparesis

14 Actively Recruiting

Phase 3, Not Applicable, Phase 1, Early Phase 1

Acne Vulgaris

0 Actively Recruiting

Pneumococcal Infections

0 Actively Recruiting

Corynebacterium minutissimum infection

0 Actively Recruiting

Acne Vulgaris

0 Actively Recruiting

Urinary Tract Infection (UTI)

6 Actively Recruiting

Phase 1, Phase 3, Phase 4, Phase 2

Urethritis

0 Actively Recruiting

Listeria monocytogenes infection

0 Actively Recruiting

Chlamydia Trachomatis

0 Actively Recruiting

Conjunctivitis

0 Actively Recruiting

penicillins

1 Actively Recruiting

Phase 3

Primary Syphilis

0 Actively Recruiting

treponema pallidum infection

0 Actively Recruiting

Communicable Diseases

0 Actively Recruiting

Erythromycin Estolate Reviews: What are patients saying about Erythromycin Estolate?

5

Patient Review

3/26/2009

Erythromycin Estolate for Stomach Muscle Paralysis and Decreased Function

4.3

Patient Review

5/18/2011

Erythromycin Estolate for Acne

I was treated for pneumonia and afterwards felt nauseous.

4

Patient Review

12/18/2013

Erythromycin Estolate for Skin Infection due to Staphylococcus Aureus Bacteria

I was given this medication for strep throat but stopped taking it after 24 hours due to severe stomach cramps, chest pains, and nausea.

2

Patient Review

3/30/2011

Erythromycin Estolate for Pneumonia caused by Bacteria

My husband has been using this drug for 38 years to treat his lympodema with great success. However, we recently ran into problems when he was prescribed a different antibiotic and developed an infection.

2

Patient Review

12/12/2009

Erythromycin Estolate for Skin Infection

1

Patient Review

3/13/2012

Erythromycin Estolate for Strep Throat

This medication has done wonders for my acne keloidalis nuchae. It's cleared up most of the area and prevented infection from spreading. However, it comes with some not-so-fun side effects like diarrhea, nausea, and increased appetite.

1

Patient Review

9/27/2010

Erythromycin Estolate for Infection of the Middle Ear caused by Streptococcus

I've been taking this for three days now and the stomach cramping has been unbearable, even when I eat. The pills are also way too big to swallow comfortably. Additionally, I have felt nauseous since starting this medication. Overall, I am not pleased with the choice of medications my doctor has prescribed.

Patient Q&A Section about erythromycin estolate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is erythromycin estolate used for?

"This medication is used to treat infections caused by certain types of bacteria. The most common uses for this medication are to treat the following: lower respiratory tract infections such as pneumonia, whooping cough, diphtheria, and Legionnaires' disease. sexually transmitted infections such as syphilis and chlamydia."

Answered by AI

Is erythromycin estolate an antibiotic?

"The traditional antibiotic for treating pertussis is erythromycin in oral form. Erythromycin estolate is considered superior to other forms, such as erythromycin ethylsuccinate or erythromycin stearate, because it results in higher drug concentrations in the serum and respiratory secretions."

Answered by AI

Is erythromycin used for cold?

"Erythromycin will not adequately address a viral infection such as the common cold or flu."

Answered by AI

Is erythromycin used for throat infection?

"Infections of the middle ear.

Erythromycin can be used to treat infections caused by streptococcal bacteria, such as strep throat and skin infections. It can also be used to treat lung infections, such as pneumonia, caused by bacteria such as streptococcal pneumoniae, mycoplasma pneumoniae, and legionella pneumophila."

Answered by AI

Clinical Trials for Erythromycin Estolate

Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting
Has No Placebo

Children's Healthcare of Atlanta (+3 Sites)

Todd Florin, MD, MSCE

Have you considered Erythromycin Estolate clinical trials?

We made a collection of clinical trials featuring Erythromycin Estolate, we think they might fit your search criteria.
Go to Trials
Image of Children's Community Pediatrics Brentwood in Pittsburgh, United States.

AI Diagnostic Support for Ear Infections

6 - 24
All Sexes
Pittsburgh, PA

Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.

Recruiting
Has No Placebo

Children's Community Pediatrics Brentwood (+1 Sites)

Timothy R Shope, MD, MPH

Merck Sharp & Dohme LLC

Image of Maternity Centre of Hamilton in Hamilton, Canada.

Rapid Test for Syphilis

13 - 49
All Sexes
Hamilton, Canada

The goal of this clinical trial is to learn if a finger-prick blood test for rapid diagnosis of syphilis infection can be implemented in a low-barrier prenatal clinic for people at risk of syphilis in pregnancy. The test gives results in 5 minutes and also tests for HIV. The main questions the study aims to answer are: * How often do pregnant people at risk of syphilis agree to the rapid test? * How well do healthcare providers perform the rapid test? * Does the rapid test speed up diagnosis and treatment of syphilis in pregnant people and their sexual partners? Participants will: * Give feedback about why they did or did not want to take the rapid test, and what their experience was taking the test; and * Share information about their health, pregnancy, and syphilis treatment (if applicable).

Recruiting
Has No Placebo

Maternity Centre of Hamilton

Laura K Erdman, MD PhD FRCPC

Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA

Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.

Recruiting
Has No Placebo

Benioff Children's Hospital - Oakland (+2 Sites)

Derek J Williams, MD, MPH

Have you considered Erythromycin Estolate clinical trials?

We made a collection of clinical trials featuring Erythromycin Estolate, we think they might fit your search criteria.
Go to Trials
Image of University of Pennsylvania Primary Care Practice in Philadelphia, United States.

Rapid Testing for Upper Respiratory Tract Infection

18+
All Sexes
Philadelphia, PA

The goal of this study is to understand the use of point of care (POC) testing devices in primary care offices to help clinicians diagnose and appropriately treat patients who have symptoms of upper respiratory infections (URIs). The study will use the BIOFIRE® SPOTFIRE® Respiratory (R) Panel testing device, which is FDA-cleared and CLIA-Waived. This panel can identify up to 15 different viruses and bacteria that can cause URIs. These POC devices will be installed in primary care clinics within the University of Pennsylvania Health System. Patients who come to the clinic with cold-like symptoms (runny nose, cough) will be offered the test. If the patient agrees to the test, their clinician will use a swab to take a small sample of fluid from their nose. This swab will then be tested within the POC device and results will be available within 15 minutes. The results of this sample will be shared with the patient, and their clinician can use the results to help decide the most appropriate medical treatment for the patient. Patients who agree to take the test will be asked to answer a short survey about the test and their experience. Clinicians will also be surveyed to share their thoughts with using the test in their clinics. Focus groups of practice staff and clinicians will also be conducted to understand any potential challenges for using this test in practice. Results from the tests and the surveys will help researchers understand the value of the test to support antibiotic stewardship efforts in primary care clinic settings.

Waitlist Available
Has No Placebo

University of Pennsylvania Primary Care Practice

Have you considered Erythromycin Estolate clinical trials?

We made a collection of clinical trials featuring Erythromycin Estolate, we think they might fit your search criteria.
Go to Trials